Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Tau biomarkers

Topic: Disease mechanisms in lab and animal studies

Plain-language summary

Chitinase-3-like protein 1 (CHI3L1) is elevated in Alzheimers disease (AD), but its role in glial dysfunction and therapeutic tractability remain unclear. Here, screening a 4.2-billion-compound DNA-encoded library identified DELC2, a brain-penetrant CHI3L1 modulator. Biophysical and crystallographic studies showed that DELC2 binds the CHI3L1 glycan-recognition groove within an aromatic-hydrophobic pocket centered on Trp99 and Trp352. DELC2 inhibited CHI3L1-RAGE association, suppressed CHI3L1-induced inflammatory signaling, reduced Gal-3-positive microglia, and restored amyloid-β uptake in glial cultures. In human cerebrospinal fluid, CHI3L1 was elevated in AD and correlated with astrocytic NF-κB activation. DELC2 phenocopied CHI3L1 immunodepletion, whereas CHI3L1 add-back restored inflammatory and amyloid-β-handling defects. Oral DELC2 achieved sustained unbound brain exposure in 5xFAD mice, improved cognitive performance, reduced multiple amyloid-β species, and attenuated astrocytic and microglial inflammatory programs. These findings establish the CHI3L1 glycan-recognition groove as a druggable regulator of RAGE-associated glial dysfunction and identify DELC2 as a chemical scaffold for CHI3L1-directed therapy in AD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Upadhyay, S., Zhang, L., Kaur, B., Calvo-Barreiro, L., Teplova, M., & Gabr, M. (2026). Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease. bioRxiv. https://doi.org/10.64898/2026.10.15.759511

Vancouver

Upadhyay S, Zhang L, Kaur B, Calvo-Barreiro L, Teplova M, Gabr M. Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease. bioRxiv. 2026. doi:10.64898/2026.10.15.759511.

BibTeX

@article{upadhyay2026-fce28563,
  author  = {Upadhyay, S. and Zhang, L. and Kaur, B. and Calvo-Barreiro, L. and Teplova, M. and Gabr, M.},
  title   = {{Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease}},
  journal = {bioRxiv},
  year    = {2026},
  doi     = {10.64898/2026.10.15.759511},
  url     = {https://doi.org/10.64898/2026.10.15.759511}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 13 of the 62 points it could be judged on, which is 21 of 100. Raw total 21 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 21 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (bioRxiv)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 13 / 62 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100.
Total 21 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Tau biomarkers from nearby years

Also tagged “inflammasome”

385 studies in the library carry the topic tag “inflammasome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 385 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →